Tranquility Partners LLC Sells 717 Shares of Johnson & Johnson (NYSE:JNJ)

Tranquility Partners LLC trimmed its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 6.9% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 9,666 shares of the company’s stock after selling 717 shares during the quarter. Tranquility Partners LLC’s holdings in Johnson & Johnson were worth $1,413,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Alliance Wealth Advisors LLC UT grew its position in Johnson & Johnson by 1.4% in the 4th quarter. Alliance Wealth Advisors LLC UT now owns 4,714 shares of the company’s stock valued at $739,000 after acquiring an additional 64 shares in the last quarter. Carolinas Wealth Consulting LLC boosted its stake in shares of Johnson & Johnson by 0.4% in the 4th quarter. Carolinas Wealth Consulting LLC now owns 16,861 shares of the company’s stock valued at $2,643,000 after buying an additional 64 shares during the period. Epic Trust Investment Advisors LLC boosted its stake in shares of Johnson & Johnson by 3.6% in the 2nd quarter. Epic Trust Investment Advisors LLC now owns 1,831 shares of the company’s stock valued at $268,000 after buying an additional 64 shares during the period. Verity Asset Management Inc. boosted its stake in shares of Johnson & Johnson by 2.0% in the 4th quarter. Verity Asset Management Inc. now owns 3,268 shares of the company’s stock valued at $512,000 after buying an additional 65 shares during the period. Finally, Forza Wealth Management LLC boosted its stake in shares of Johnson & Johnson by 0.8% in the 2nd quarter. Forza Wealth Management LLC now owns 8,742 shares of the company’s stock valued at $1,278,000 after buying an additional 66 shares during the period. 69.55% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. TD Securities decreased their price objective on Johnson & Johnson from $195.00 to $185.00 in a research note on Thursday, July 18th. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Friday, August 16th. Sanford C. Bernstein boosted their target price on Johnson & Johnson from $161.00 to $171.00 in a research note on Thursday, July 18th. Daiwa Capital Markets cut Johnson & Johnson from an “outperform” rating to a “neutral” rating and decreased their target price for the stock from $160.00 to $150.00 in a research note on Tuesday, July 23rd. Finally, Daiwa America cut Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 23rd. Seven equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $173.21.

Johnson & Johnson Trading Up 1.1 %

NYSE:JNJ opened at $164.13 on Monday. The firm has a market cap of $395.01 billion, a P/E ratio of 10.23, a PEG ratio of 2.63 and a beta of 0.52. The company has a current ratio of 1.07, a quick ratio of 0.85 and a debt-to-equity ratio of 0.44. The stock’s 50 day simple moving average is $153.92 and its 200-day simple moving average is $153.20. Johnson & Johnson has a 12-month low of $143.13 and a 12-month high of $167.78.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, July 17th. The company reported $2.82 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.71 by $0.11. The business had revenue of $22.45 billion for the quarter, compared to analyst estimates of $22.33 billion. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%. The company’s revenue for the quarter was up 4.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.80 earnings per share. Equities analysts anticipate that Johnson & Johnson will post 10.07 EPS for the current year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Tuesday, August 27th will be issued a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.02%. The ex-dividend date of this dividend is Tuesday, August 27th. Johnson & Johnson’s payout ratio is currently 30.92%.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.